QuickView for YDL103C;jsessionid=15F15BB478DC6C77651BC16CE76A6F8A;jsessionid=FA09DD4A5D65571BA1AD979499E356E2;jsessionid=5DB5107377C50D220B2B02849FAC3A0E;jsessionid=161EA4FB6A70DC430F4519468CC7F620;jsessionid=696890CAB45EBF2E3C87D2130F1D510F;jsessionid=DFECE6B915F61453DBC70F60C514FA19;jsessionid=CD1CA357D0C087BC529470552FBFA40B;jsessionid=ACA739C5C7BCEAB0830E97EB22A9F0A0;jsessionid=B431E01C90B25939523D6D82D081B553;jsessionid=6B48308F40C79CDC201EE49A9E04B40A;jsessionid=0454378796661B809E070F7C4C34B356;jsessionid=480AF80D54267DA440BD46A19A38934E (gene)

1. Cyst fluid glycoproteins accurately distinguishing malignancies of pancreatic cystic neoplasm.
2. Clinical Evaluation of Cystic Renal Masses With Bosniak Classification by Contrast-Enhanced Ultrasou…
3. Feasibility of Surveillance for Mucinous Cystic Neoplasm of the Pancreas: A Multi-Institutional Retr…
4. Clinicopathological and genetic characteristics of congenital cystic adenomatoid malformation of lun…
5. The added value of contrast-enhanced ultrasound in evaluation of indeterminate small solid renal mas…

There were no clinical trials for YDL103C;jsessionid=15F15BB478DC6C77651BC16CE76A6F8A;jsessionid=FA09DD4A5D65571BA1AD979499E356E2;jsessionid=5DB5107377C50D220B2B02849FAC3A0E;jsessionid=161EA4FB6A70DC430F4519468CC7F620;jsessionid=696890CAB45EBF2E3C87D2130F1D510F;jsessionid=DFECE6B915F61453DBC70F60C514FA19;jsessionid=CD1CA357D0C087BC529470552FBFA40B;jsessionid=ACA739C5C7BCEAB0830E97EB22A9F0A0;jsessionid=B431E01C90B25939523D6D82D081B553;jsessionid=6B48308F40C79CDC201EE49A9E04B40A;jsessionid=0454378796661B809E070F7C4C34B356;jsessionid=480AF80D54267DA440BD46A19A38934E